Oncologic Outcome of Metastasectomy for Urothelial Carcinoma: Who Is the Best Candidate?-Reference-Cited by-同舟云学术

Oncologic Outcome of Metastasectomy for Urothelial Carcinoma: Who Is the Best Candidate?

Published:2017-07-07 Issue:9 Volume:24 Page:2794-2800
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Nakagawa Tohru,Taguchi Satoru,Kanatani Atsushi,Kawai Taketo,Ikeda Masaomi,Urakami Shinji,Matsumoto Akihiko,Komemushi Yoshimitsu,Miyakawa Jimpei,Yamada Daisuke,Suzuki Motofumi,Enomoto Yutaka,Nishimatsu Hiroaki,Kondo Yasushi,Nagase Yasushi,Hirano Yoshikazu,Okaneya Toshikazu,Tanaka Yoshinori,Miyazaki Hideyo,Fujimura Tetsuya,Fukuhara Hiroshi,Kume Haruki,Igawa Yasuhiko,Homma Yukio

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/article/10.1245/s10434-017-5970-8/fulltext.html

Reference27 articles.

1. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:1066–73.

2. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–08.

3. Sonpavde G, Watson D, Tourtellott M, et al. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. Clin Genitourin Cancer. 2012;10:1–5. doi: 10.1016/j.clgc.2011.11.005 .

4. Nakagawa T, Hara T, Kawahara T, et al. Prognostic risk stratification of patients with urothelial carcinoma of the bladder with recurrence after radical cystectomy. J Urol. 2013;189:1275–81. doi: 10.1016/j.juro.2012.10.065 .

5. Nakagawa T, Taguchi S, Uemura Y, et al. Nomogram for predicting survival of postcystectomy recurrent urothelial carcinoma of the bladder. Urol Oncol. 2017;35:457.e15–e21. doi: 10.1016/j.urolonc.2016.12.010 .

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review;Japanese Journal of Clinical Oncology;2023-12-18

2. Development and validation a model for predicting overall survival of bladder cancer with lung metastasis: a population-based study;European Journal of Medical Research;2023-08-10

3. Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants;Frontiers in Oncology;2022-04-19

4. Pretreatment serum C-reactive protein is a significant prognostic factor in patients with soft tissue metastases;Journal of Orthopaedic Science;2021-05

5. Safety and Activity of Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors for Platinum-Resistant Urothelial Cancer: A Meta-Analysis of Published Clinical Trials;Frontiers in Oncology;2021-04-01